Methodological challenges in pragmatic trials in Alzheimer's disease and related dementias: Opportunities for improvement

被引:6
|
作者
Taljaard, Monica [1 ,2 ]
Li, Fan [3 ]
Qin, Bo [3 ]
Cui, Caroline [3 ]
Zhang, Leyi [3 ]
Nicholls, Stuart G. [1 ]
Carroll, Kelly [1 ]
Mitchell, Susan L. [4 ]
机构
[1] Ottawa Hosp Res Inst, Clin Epidemiol Program, Civ Campus,1053 Carling Ave,Civ Box 693, Ottawa, ON K1Y 4E9, Canada
[2] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[3] Yale Univ, Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[4] Hebrew Senior Life Marcus Inst Aging Res, Boston, MA USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Cluster randomized trials; longitudinal data analysis; multilevel modeling; missing data; intracluster correlation; pragmatic trials; Alzheimer's disease; dementia; COVARIATE-DEPENDENT MISSINGNESS; SAMPLE-SIZE DETERMINATION; CLINICAL-TRIALS; OUTCOMES; DESIGN; POWER;
D O I
10.1177/17407745211046672
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aims We need more pragmatic trials of interventions to improve care and outcomes for people living with Alzheimer's disease and related dementias. However, these trials present unique methodological challenges in their design, analysis, and reporting-often, due to the presence of one or more sources of clustering. Failure to account for clustering in the design and analysis can lead to increased risks of Type I and Type II errors. We conducted a review to describe key methodological characteristics and obtain a "baseline assessment" of methodological quality of pragmatic trials in dementia research, with a view to developing new methods and practical guidance to support investigators and methodologists conducting pragmatic trials in this field. Methods We used a published search filter in MEDLINE to identify trials more likely to be pragmatic and identified a subset that focused on people living with Alzheimer's disease or other dementias or included them as a defined subgroup. Pairs of reviewers extracted descriptive information and key methodological quality indicators from each trial. Results We identified N = 62 eligible primary trial reports published across 36 different journals. There were 15 (24%) individually randomized, 38 (61%) cluster randomized, and 9 (15%) individually randomized group treatment designs; 54 (87%) trials used repeated measures on the same individual and/or cluster over time and 17 (27%) had a multivariate primary outcome (e.g. due to measuring an outcome on both the patient and their caregiver). Of the 38 cluster randomized trials, 16 (42%) did not report sample size calculations accounting for the intracluster correlation and 13 (34%) did not account for intracluster correlation in the analysis. Of the 9 individually randomized group treatment trials, 6 (67%) did not report sample size calculations accounting for intracluster correlation and 8 (89%) did not account for it in the analysis. Of the 54 trials with repeated measurements, 45 (83%) did not report sample size calculations accounting for repeated measurements and 19 (35%) did not utilize at least some of the repeated measures in the analysis. No trials accounted for the multivariate nature of their primary outcomes in sample size calculation; only one did so in the analysis. Conclusion There is a need and opportunity to improve the design, analysis, and reporting of pragmatic trials in dementia research. Investigators should pay attention to the potential presence of one or more sources of clustering. While methods for longitudinal and cluster randomized trials are well developed, accessible resources and new methods for dealing with multiple sources of clustering are required. Involvement of a statistician with expertise in longitudinal and clustered designs is recommended.
引用
收藏
页码:86 / 96
页数:11
相关论文
共 50 条
  • [1] Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
    Stoeckel, Luke E.
    Fazio, Elena M.
    Hardy, Kristina K.
    Kidwiler, Nicole
    Mclinden, Kristina A.
    Williams, Benfeard
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2025, 11 (01)
  • [2] New challenges and future perspectives in Alzheimer's disease and related dementias
    Liu, Gong-Ping
    Wang, Shuo
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [3] Alzheimer's Disease and Related Dementias
    Sanders, Sara
    Morano, Carmen
    JOURNAL OF GERONTOLOGICAL SOCIAL WORK, 2008, 50 (01): : 191 - 214
  • [4] Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias
    Dokholyan, Nikolay, V
    Mohs, Richard C.
    Bateman, Randall J.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
  • [5] ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (HS)
    不详
    INNOVATION IN AGING, 2022, 6 : 1 - 1
  • [6] Prognostication in Alzheimer's disease and related dementias
    Ernecoff, Natalie C.
    Wessell, Kathryn L.
    Hanson, Laura C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2025, 73 (01) : 329 - 332
  • [7] Psychopathology in Alzheimer's disease and related dementias
    Hargrave, R
    Stoeklin, M
    Haan, M
    Reed, B
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 367 - 367
  • [8] ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (HS)
    不详
    PEDIATRIC CRITICAL CARE MEDICINE, 2022, 23 : 1 - 146
  • [9] Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias
    Tahmi, M.
    Luchsinger, Jose A.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2023, 10 (04): : 706 - 717
  • [10] Metformin in the Prevention of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias
    M. Tahmi
    José A. Luchsinger
    The Journal of Prevention of Alzheimer's Disease, 2023, 10 : 706 - 717